“FORMULATION, OPTIMIZATION AND EVAULATION OF …



PREPARATION AND IN-VITRO EVALUATION OF AMOXICILLIN ORAL MEDICATED JELLY

SYNOPSIS FOR

M.PHARM DISSERTATION

SUBMITTED

TO

RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES

BANGALORE, KARNATAKA.

[pic]

BY

VINOD KUMAR

Ι M.PHARM

DEPARTMENT OF PHARMACEUTICS,

M.E.S COLLEGE OF PHARMACY,

ARADESHAHALLY GATE,

BANGALORE-562110,

KARNATAKA.

(2010-2011)

1

2

3

4

5

6

7

8 ANNEXURE-II

PROFORMA FOR REGISTRATION OF SUBJECTS FOR P.G. DISSERTATION

| | |Mr. VINOD KUMAR |

|1. |NAME OF THE CANDIDATE AND ADDRESS |M.E.S COLLEGE OF PHARMACY, |

| |(IN BLOCK LETTERS) |ARADESHAHALLY GATE, |

| | |BANGALORE-.562110, KARNATAKA. |

| | | |

|2. |NAME OF THE INSTITUTION |M.E.S COLLEGE OF PHARMACY, |

| | |ARADESHAHALLY GATE, |

| | |BANGALORE-.562110, KARNATAKA |

| | | |

|3. |COURSE OF STUDY AND SUBJECT |MASTER OF PHARMACY |

| | |IN |

| | |PHARMACEUTICS |

| | | |

|4. |DATE OF THE ADMISSION |30/09/2010 |

| | |

|5. |TITLE OF THE TOPIC: |

| | |

| | |

| | |

| | |

| | |

| |“PREPARATION AND IN-VITRO EVALUATION OF AMOXICILLIN ORAL MEDICATED JELLY” |

| | |

| | |

| | |

| | |

| | |

| | |

| |BRIEF RESUME OF THE INTENDED WORK |

| | |

|6. |6.1NEED FOR THE STUDY |

| |Despite tremendous advancement in drug delivery (4), oral route remains the preferred route for the administration of therapeutic agents, low cost |

| |of therapy and ease of administration leads to patient compliance. So most of the paediatric formulations also available in different types of oral |

| |dosage forms, like syrups, suspensions, reconstituted powders, dispersible tablets, mini tablets etc. But so many problems are arising in usage of |

| |that type of formulations in paediatrics, like stability, dosage wastage, dose dumping etc., and also the children’s are not showing the interest to|

| |take such type of formulations, and need so much counseling to the mothers to use the above type of formulations in the right directions to their |

| |babies. Inconvenience of administration and patient compliance are gaining significant importance in the design of dosage forms. So the present |

| |investigation is focused to prepare an elegant, stable and most acceptable oral medicated jelly dosage form of amoxicillin(2) using suitable |

| |combination of excipients like sodium alginate as a gelling agent and sodium citrate as a source of cation, and to improve its efficacy. |

| |Jellies (1,3) are transparent or translucent, non greasy and mucilage type products. They are generally applied externally for medication, |

| |lubrication and some miscellaneous applications. Jellies contains considerable amount of water and are particularly suitable for water soluble |

| |medicaments. These are semisolid to thick viscous fluids that consist of sub microscopic particles in a somewhat rigid or plastic vehicle. The jelly|

| |dosage form can be swallowed easily without water and are soft and smooth. |

| |Amoxicillin(12), is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis; gonorrhea; and infections of the ears, nose,|

| |throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. |

| |Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. Antibiotics will not work |

| |for colds, flu, and other viral infections. Amoxicillin is a moderate-spectrum, bacteriolytic, β-lactum antibiotics used to treat bacterial |

| |infections caused by susceptible microorganisms. It is usually the drug of choice within the class because it is better absorbed, following oral |

| |administration, than other β-lactam antibiotics. Amoxicillin is one of the most common antibiotics prescribed for children. Amoxicillin also is used|

| |sometimes to prevent anthrax infection after exposure and to treat anthrax infection of the skin and chlamydia infections during pregnancy. |

| | |

| |Mechanism of action; |

| |This drug acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that |

| |make up a major component of the cell walls of both Gram-positive and Gram-negative bacteria. It has two ionisable groups in the physiological range|

| |(the amino group in alpha-position to the amide carbonyl group and the carboxyl group). |

| | |

| |[pic] |

| |Systematic(IUPAC)name; (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic|

| |acid trihydrate. |

| | |

| |Dose; Adults and children >20 kg: 250 mg every 8 hours. Children 20 kg; 40 mg/kg/day in divided doses every 8 hours for children ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download